Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial for COVID-19 in NEJM
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis
Shots:
- The P-III trial evaluates the efficacy and safety of REGEN-COV (casirivimab and imdevimab, 1200/2400mg) vs PBO in a non-hospitalized patient with COVID-19
- The trial met its 1EPs & 2EPs i.e., 70% reduction in the risk of hospitalization or death in high-risk non-hospitalized patients & the safety profile was consistent with a previously reported data
- Additionally, multiple analyses showed that the Ab cocktail retains potency against the variants of concern circulating within the US. REGEN-COV is available for free to eligible patients in the US as part of a US government-funded program
Click here to read full press release/ article | Ref: PR Newswire | Image: The Print